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A B S T R A C T
Nephronophthisis is one of the leading genetic causes of end-stage renal disease in childhood. Early diagnostics
and prognostics for nephronophthisis are currently limited. We aimed to identify non-invasive protein bio-
markers for nephronophthisis in urinary extracellular vesicles. Extracellular vesicles were isolated from urine of
12 patients with a nephronophthisis-related ciliopathy and 12 age- and gender-matched controls, followed by in-
depth label-free LC-MS/MS proteomics analysis of gel fractionated extracellular vesicle proteins. Supervised
cluster analysis of proteomic profiles separated patients from controls. We identified 156 differentially expressed
proteins with fold change ≥4 in patients compared to controls (P < .05). Importantly, expression levels of
discriminating proteins were correlated with chronic kidney disease stage, suggesting possible applications for
urinary extracellular vesicle biomarkers in prognostics for nephronophthisis. Enrichment analysis of gene on-
tology terms revealed GO terms including signaling, actin cytoskeleton and endocytosis among the down-
regulated proteins in patients, whereas terms related to response to wounding and extracellular matrix orga-
nization were enriched among upregulated proteins. Our findings represent the first step towards a non-invasive
diagnostic test for nephronophthisis. Further research is needed to determine specificity of the candidate bio-
markers. In conclusion, proteomic profiles of urinary extracellular vesicles differentiate nephronophthisis-re-
lated ciliopathy patients from healthy controls.
Significance: Nephronophthisis is an important cause of end-stage renal disease in children and is associated with
an average diagnostic delay of 3.5 years. This is the first study investigating candidate biomarkers for ne-
phronophthisis using global proteomics analysis of urinary extracellular vesicles in patients with ne-
phronophthisis compared to control individuals. We show that measuring protein markers in urinary extra-
cellular vesicles is a promising approach for non-invasive early diagnostics of nephronophthisis.
1. Introduction
Nephronophthisis is an important genetic cause of end-stage renal
disease (ESRD) in children and young adults, accounting for 2.4% to
15% of pediatric ESRD cases [1–3]. Nephronophthisis is known to result
from defective ciliary signaling and has been classified as a renal ci-
liopathy. It is characterized by chronic tubulointerstitial nephritis
leading to loss of renal function and a reduced concentrating ability of
the kidney. The diagnosis of nephronophthisis is currently based on
clinical symptoms including polydipsia, polyuria, growth retardation
and refractory anemia, chronic kidney disease (CKD) and a family
history consistent with autosomal recessive disease [3, 4]. Renal ul-
trasound findings include hyperechogenic kidneys and corticomedul-
lary cysts in approximately 50% of patients [5–7].
As a result of the variable and non-specific presenting symptoms,
nephronophthisis is diagnosed on average 3.5 years after symptom
onset, often in advanced stages of CKD when kidney damage is irre-
versible [7]. This diagnostic delay occurs especially in
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nephronophthisis patients without extra-renal manifestations (e.g. re-
tinitis pigmentosa or neurological signs) that could be indicative of a
ciliopathy and would usually prompt monitoring of renal function. In
addition, DNA testing currently confirms the diagnosis in only 40–50%
of nephronophthisis patients and genetic confirmation does not enable
accurate prognostics yet, hindering disease management and genetic
counseling [8–10]. Therefore, the discovery of early biomarkers for
nephronophthisis-related ciliopathies (NPH-RC) is essential to permit
early diagnostics and monitoring of disease progression. Early diag-
nostics will permit ‘reverse phenotyping’, i.e. the monitoring of other
ciliopathy-related features such as retinal degeneration and liver fi-
brosis in apparently isolated nephronophthisis. Furthermore, early di-
agnostics will pave the way for timely supportive treatment, aimed at
slowing down disease progression towards ESRD, and preparation for
pre-emptive renal transplantation. Additionally, early detection of ne-
phronophthisis may be indispensable for the success of future targeted
therapies.
Biofluids contain extracellular vesicles (EVs) including exosomes
that have emerged as a treasure trove of molecular markers [11].
Exosomes originate from 50 to 130 nm intraluminal vesicles of multi-
vesicular bodies that are secreted into extracellular fluids [12]. Exo-
somes are important mediators of intercellular communication [13].
The content of exosomes has been shown to reflect the physiological
state of the cells of origin, in the case of urine the cells lining the kidney
and urinary tract [14]. Previous studies have shown that proteomic
analysis of urinary exosomes offers unique insights into pathophysio-
logical mechanisms that underlie kidney disease [15]. Thus, urinary
exosomes are an excellent non-invasive source of biomarkers for kidney
diseases [16].
Here, we present the first study identifying candidate biomarkers for
nephronophthisis using global proteomics analysis of urinary EVs in 12
NPH-RC patients compared to 12 control individuals. The identification
of biomarkers for nephronophthisis gives us opportunities to develop a
non-invasive diagnostic test for children suspected of nephronophthisis
and thereby improve the care for NPH-RC patients. When confirmed in
larger patient series, we see promising applications in diagnostics and
prognostics and, thereby, translation to clinical practice.
2. Materials and methods
2.1. Patients and urine collection
Twelve patients with NPH-RC and 12 age- and gender-matched
control subjects were recruited at the Department of Pediatric
Nephrology of the University Medical Center Utrecht, the Department
of Genetics of the University Medical Center Utrecht, and the
Department of Human Genetics of the Radboudumc Nijmegen. NPH-RC
patients and controls were included in the AGORA (Aetiologic research
into Genetic and Occupational/environmental Risk factors for con-
genital Anomalies) data- and biobank project, approved by the regional
Committee on Research involving Human Subjects (CMO Arnhem-
Nijmegen 2006/048 and METC UMC Utrecht 12–473). Signed informed
consent was obtained for all subjects included in this study. Inclusion
criteria for patients were a molecularly confirmed diagnosis of NPH-RC
or a high suspicion thereof, based on clinical features including pre-
sence of polyuria, absence of recurrent urinary tract infections, CKD
stage 1–5 [17], renal ultrasound showing parenchymal damage but
absence of malformation of the kidneys and urinary tract, urinalysis
showing absence of hematuria, erythrocyte casts and proteinuria in the
nephrotic range, and exclusion of other causes of early-onset renal
failure. Age and gender-matched control subjects were acquaintances of
the researchers and showed no signs or symptoms of NPH-RC, no family
history of pediatric-onset renal disease, no known congenital anomalies
of the kidney and urinary tract, no consanguinity, and a protein/crea-
tinine ratio within the normal range (i.e. < 20mg/mmol in individuals
over 2 years of age). Control urine samples were anonymized after
collection and matching.
Urine samples (40 to 400ml) were collected from all subjects using
sterile urine containers and kept on ice for a maximum of 5 h until
processing. We did not use the first morning void to minimize the
chance for an enrichment of EVs derived from the urinary bladder. A
4 μl aliquot of fresh urine was stored at −20 °C for determination of
protein/creatinine ratio using the Bradford Protein Assay (Bio-Rad,
Hercules, CA, USA) and the Creatinine PAP FS kit (DiaSys Diagnostic
Systems, Holzheim, Germany) according to manufacturers' instructions.
The remainder of the urine was centrifuged at 500×g for 10min at 4 °C
and at 2000 g for 20min at 4 °C. Supernatants were stored at −80 °C
until further use.
2.2. EV isolation
Supernatants were processed in three batches of eight subjects with
equal numbers of patients and controls, male and female subjects and
uniform mean subject age to preclude batch effects. Thawed super-
natants were centrifuged at 2000×g for 20min at 4 °C. 0.05% NP-40
(Sigma-Aldrich, Zwijndrecht, The Netherlands) was added to each su-
pernatant as a detergent [18]. The samples were concentrated to 1ml
by centrifugation at 4000×g at room temperature using Amicon Ul-
tracel 100 kDa cut-off centrifugal filters (Merck Millipore, Billerica, MA,
USA), which removes proteins smaller than 100 kDa while retaining
extracellular vesicles. Concentrated samples were diluted to 1.9ml
using PBS (BBraun, Melsungen, Germany). Subsequently, 100 μl cOm-
plete™, Mini, EDTA-free Protease Inhibitor Cocktail (PIC) (Roche, Basel,
Switzerland) in 525 μl PBS was added to each sample. Urine was cen-
trifuged for 16,000×g for 30min at 4 °C to remove debris. Next, Vn96
peptide (ME-kit, New England Peptide, Gardner, MA, USA) was added
to the supernatant to aggregate EVs including exosomes as previously
described [19, 20]. The Vn96 peptide binds heat shock proteins present
on the surface of EVs, allowing ‘miniprep’ isolation. Samples were in-
cubated for 60min at room temperature and centrifuged at 16,000×g
for 15min at 4 °C. The full pellets were washed with 5% cOmplete™ PIC
in PBS, centrifuged at 16,000×g for 15min at 4 °C and resuspended in
2ml NuPAGE Sample Buffer (Life Technologies, Thermo Fisher Scien-
tific, Carlsbad, CA, USA).
Table 1
Subject and urine characteristics.
Subject characteristics Patients Controls
Number (n) 12 12
Gender (M/F) 6/6 6/6
Age (years; mean ± SD) 14.8 (± 4.7) 14.7 (±4.7)
Diagnosis Isolated NPH
(n= 6)
BBS (−like)
(n= 2)
CED (n= 2)
JBTS (n= 2)
NA
CKD stage I (n= 1)
II (n= 3)
III (n= 4)
IV (n= 3)
V (n=1)
NA
Urine characteristics Patients Controls
Amount (ml; mean ± SD) 113.3 (± 98.0) 90.0 (± 14.3)
Processing time (minutes; mean ± SD) 103.8 (± 79.0) 46.7 (± 41.1)
Storage time (days; mean ± SD) 119.6 (± 62.3) 95.0 (± 63.9)
Protein/creatinine ratio (mg/mmol
mean ± SD)
58.0 (± 64.2) 11.6 (± 8.5)
NPH: nephronophthisis; BBS: Bardet-Biedl syndrome; CED: cranioectodermal
dysplasia (Sensenbrenner syndrome); JBTS: Joubert syndrome; NA: not ap-
plicable.
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2.3. Western blot
Immunoblotting was performed in additional control urine samples
to verify the isolation of EVs. Antibodies were directed against EV
markers PDCD6IP (Alix, Mouse monoclonal; 1:1000; Cell signaling
Technology, Danvers, MA, USA) and TSG101 (Rabbit polyclonal; 1:500;
Atlas Antibodies, Bromma, Sweden) (Supplementary Fig. 1).
2.4. Gel electrophoresis and in-gel tryptic digestion
Sonified EV samples were size separated on NuPAGe Novex 4–12%
Bis-Tris Protein Gels (Life Technologies, Thermo Fisher Scientific,
Carlsbad, CA, USA) using one-dimensional gel electrophoresis. This
eliminates contaminants and reduces sample complexity to improve
peptide identification. Gels were processed with reducing and alky-
lating agents. Gels were cut prior to in-gel digestion with trypsin fol-
lowed by peptide extraction as previously described [20, 21]. Extracts
were stored at −20 °C until further use.
2.5. Nano-LC-MS/MS and database searching
Extracted peptides were concentrated in a vacuum centrifuge and
the volume was adjusted using 4% acetonitrile in 0.5% trifluoro-acetic
acid (TFA) acid to achieve equal protein loading based on gel images.
Peptides were separated using nanoscale liquid chromatography and
analyzed using tandem mass spectrometry (GelC-MS/MS) as previously
described [22–24]. Briefly, peptides were separated by an Ultimate
3000 nanoLC-MS/MS system (Dionex LC-Packings, Amsterdam, The
Netherlands) equipped with a 40 cm×75 μm ID fused silica column
custom packed with 1.9 μm 120 Å ReproSil Pur C18 aqua (Dr Maisch
GMBH, Ammerbuch-Entringen, Germany). After injection, peptides
were trapped at 6 μl/min on a 10mm×100 μm ID trap column packed
with 5 μm 120 Å ReproSil Pur C18 aqua in 0.05% formic acid. Peptides
were separated at 300 nl/min in a 10–40% gradient (buffer A: 0.5%
acetic acid (Fischer Scientific), buffer B: 80% ACN (Biosolve), 0.5%
acetic acid) in 60min (90min inject-to-inject) at 35 °C. Eluting peptides
were ionized at a potential of +2 kVa into a Q Exactive mass spec-
trometer (Thermo Fisher, Bremen, Germany). Intact masses were
measured at resolution 70.000 (at m/z 200) in the orbitrap using an
AGC target value of 3E6 charges. The top 10 peptide signals (charge-
states 2+ and higher) were submitted to MS/MS in the HCD (higher-
energy collision) cell (1.6 amu isolation width, 25% normalized colli-
sion energy). MS/MS spectra were acquired at resolution 17.500 (at m/
z 200) in the orbitrap using an AGC target value of 1E6 charges, a
maxIT of 60ms and an underfill ratio of 0.1%. Dynamic exclusion was
applied with a repeat count of 1 and an exclusion time of 30 s. MS/MS
spectra were searched against the Swissprot database (2015–09, 42,122
Fig. 1. Study methodology to identify differentially expressed proteins in ne-
phronophthisis patients compared to age- and gender-matched controls. Venn
diagram shows total number of proteins identified in controls and in patients
based on raw spectral counts. NPH: isolated nephronophthisis; BBS: Bardet-
Biedl syndrome; CED: cranioectodermal dysplasia (Sensenbrenner syndrome);
JBTS: Joubert syndrome.
Fig. 2. Volcano plot of differentially regulated proteins in patients compared to
controls. Dots represent individual proteins. Proteins were detected in at least 8
of 12 samples and had a mean normalized count in positive samples of ≥2.
Vertical dashed lines mark fold change=4 and horizontal dashed line marks
the significance threshold P < .05. Top 5 most downregulated proteins (blue)
and upregulated proteins (red) by fold change were highlighted and labeled
with protein names. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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entries) using MaxQuant software (version 1.5.2.8) [25], with a max-
imum allowed deviation of 4.5 ppm for the precursor mass and 20 ppm
the for fragment masses. Cysteine carboxamidomethylation was treated
as fixed modification and N-acetylation and methionine oxidation were
treated as variable modifications. Identified peptides and proteins were
filtered to a false discovery rate of 1% using the target-decoy method
[26]. Raw spectral counts of identified protein groups were processed
using R for further analysis.
2.6. Data mining and statistical analyses
Spectral counts were normalized using the average of the sum of
raw counts across all samples as previously described [27]. Protein
expression differences between patients and controls were calculated
using the beta-binominal test for unpaired data [28, 29]. The P-va-
lues< .05 were considered statistically significant. R package gplots
was used to perform hierarchical clustering [30].
Differentially expressed proteins were identified using stringent
selection criteria: P < .05, fold change ≥4 for down- and≥ 3 for
upregulated proteins, detected in at least 8 of 12 samples and a mean
normalized count in positive samples of ≥2. Human gene symbols
corresponding to protein identifiers of differentially expressed proteins
were imported into the STRING tool (version 10.0) to examine protein-
protein interactions [31]. Interaction networks were annotated using
Cytoscape (version 3.4.0) [32]. The PANTHER overrepresentation test
in AmiGO 2 (version 2.4.24) was used for GO term enrichment analysis
[33, 34]. Bonferroni-corrected P-values< .05 were considered statis-
tically significant. ConsensusPathDB (version 31) was used to analyze
enriched biological pathways per annotated gene cluster [35].
Interaction databases that contained> 50% drug-target and biochem-
ical interactions were excluded from pathway enrichment analyses
because they were considered irrelevant to the aims of the present
study. Further statistical analyses, including correlation analyses of
protein expression with CKD stage, were performed using Graph Pad
Prism (Version 7.02). Finally, a PubMed literature search was per-
formed for comparison of proteins that were previously associated with
CKD with discriminating markers identified in the current study (Sup-
plementary Methods). The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium via the PRIDE [36]
partner repository with the dataset identifier PXD009784.
3. Results
3.1. Differentially expressed proteins discriminate between NPH-RC patients
and controls
Twelve patients with NPH-RC and 12 age-and gender-matched
control subjects, age 6 to 25 years, were recruited for urine collection
(Table 1). Patients' phenotypes included isolated nephronophthisis
(NPH; n=6), Bardet-Biedl syndrome (BBS; n=2), Sensenbrenner
syndrome (CED; n= 2), and Joubert syndrome (JBTS; n=2). Urine
protein/creatinine ratio was determined in each subject to confirm
patient or control status with a normal range of< 20mg/mmol in in-
dividuals over 2 years of age. The mean protein/creatinine ratio was
58.0 ± 64.2mg/mmol in NPH-RC patients compared to
11.6 ± 8.5mg/mmol in control individuals. Supplementary Table 1
contains an overview of the sample details.
Proteomic profiles of urinary EVs were determined in each patient
Fig. 3. Supervised hierarchical clustering of normalized protein counts (P < .05) separates NPH-RC patients from controls. Three separate clusters (marked 1,2 and
3) can be discerned. Blue represents downregulated proteins and orange represents upregulated proteins. NPH: isolated nephronophthisis; BBS: Bardet-Biedl syn-
drome; CED: cranioectodermal dysplasia (Sensenbrenner syndrome); JBTS: Joubert syndrome. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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and control individual by using EV protein fractionation by gel elec-
trophoresis in conjunction with nanoLC-MS/MS. In total, 2935 unique
EV proteins were identified, of which 2284 proteins were present in
both patients and controls (Fig. 1, Supplementary Tables 2 and 3). Nine
hundred ten proteins were differentially expressed in NPH-RC patients
compared to controls (P < .05), of which 598 proteins were down-
regulated and 312 proteins were upregulated. Out of 910 statistically
significant differentially expressed urinary EV proteins, 156 proteins
met stringent criteria for potential biomarker selection (fold change
≥4, detected in at least 8 of 12 samples and a mean normalized count
in positive samples of ≥2) (Fig. 2). Of the proteins that met these cri-
teria, 114 proteins were downregulated and 42 proteins were upregu-
lated (Supplementary Table 4).
Supervised hierarchical clustering of normalized protein counts
showed a near-complete separation of patient and control samples
(Fig. 3). Three separate clusters were discerned: 1) a cluster of 5 control
samples, 2) a central cluster of 4 patients (patient 2, 3, 6 and 10) po-
sitioned among 7 controls, and 3) a cluster of 8 patient samples. The
average CKD stage of patients in cluster 3 comprising 8 patient samples
was higher compared to the mean CKD stage of patients in the central
cluster (CKD stage 3–4 versus CKD stage 2, respectively), suggesting
that proteomic profiles from patients with a more advanced CKD stage
cluster together. Patient 10 with a tentative genetic diagnosis (a mu-
tation and a variant of unknown significance (VUS) in NPHP4,
Supplementary Table 5) clustered in the central cluster among controls.
Patients without a molecular diagnosis (patients 1 and 8) clustered
together with patients with a molecular diagnosis in the third cluster. In
addition, protein-clustering analyses after stratification into different
diagnostic subgroups (i.e. isolated nephronophthisis, Bardet-Biedl syn-
drome, Sensenbrenner syndrome, and Joubert syndrome) showed se-
paration between patients and matched controls except in isolated ne-
phronophthisis, in which patient 10 grouped among controls
(Supplementary Fig. 2).
3.2. Expression levels of differentiating proteins are correlated with CKD
stage
To assess the relationship between the expression level of dis-
criminating proteins and CKD stage in NPH-RC patients, mean nor-
malized counts of individual proteins were compared between controls
and patients with CKD stage 1–2 (n= 4), CKD stage 3 (n=4) and CKD
stage 4–5 (n=4), respectively. The mean normalized protein counts of
down- and upregulated proteins were correlated with CKD stage in
NPH-RC patients by showing increasing downregulation or upregula-
tion with advancing disease stage (P < .05) (Fig. 4). The expression
levels of the most highly abundant downregulated proteins (DPEP1 and
FAT4) and upregulated protein (VCAN) clearly illustrated this correla-
tion (Table 2). These findings indicate enhanced deregulation of pro-
teins within urinary EVs of patients with advanced CKD stage and
suggest a prognostic value for the discriminating proteins.
3.3. Differentially expressed proteins show enrichment for signaling
pathways and response to tissue damage
Enrichment analysis for gene ontology (GO) terms related to 1)
biological processes, 2) cellular components, and 3) molecular func-
tions as well as pathway analysis was performed to gain insight into the
functionality of 156 discriminating markers in NPH-RC patients. Sixty-
eight GO terms related to biological processes were significantly en-
riched among 114 downregulated proteins in patients. Top enriched GO
terms included multiple signaling pathways, ‘regulation of actin cy-
toskeleton reorganization’ and ‘regulation of endocytosis’ (Fig. 5A).
Signaling pathways included ‘insulin receptor signaling’, ‘FC-gamma
receptor signaling’ and ‘small GTPase-mediated signal transduction’.
Forty-two out of 156 proteins were upregulated. This number was too
small for GO term and pathway analyses. To enable broader GO term
and pathway analyses, a less stringent fold change of ≥3 was applied
for upregulated proteins, resulting in 70 instead of 42 upregulated
proteins. Among 70 upregulated proteins, 31 GO terms related to bio-
logical processes were significantly enriched, including ‘positive reg-
ulation of cell-substrate adhesion’, ‘extracellular matrix organization’
and ‘response to wounding’. These results seem to reflect kidney da-
mage in general, present in the NPH-RC patients, rather than ciliopathy-
specific processes.
Overrepresented GO terms related to cellular components corre-
sponding to both down- and upregulated proteins included ‘extra-
cellular exosome’ and ‘cytoplasmic vesicle’, which are both related to
EVs, ‘adherens junction’ and ‘cortical cytoskeleton’ (Fig. 5B). Of note,
there was a two- to threefold decrease in mean normalized spectral
counts of EV markers TSG101 and PDCD6IP in patients compared to
controls (P= .0025, calculated using Mann-Whitney test), possibly
accounting for the overrepresentation of EV-related GO terms among
downregulated proteins. Enriched GO terms related to molecular
function showed mainly terms related to enzymatic and binding activity
(Fig. 5C).
Pathway analysis was performed using ConsensusPathDB to identify
overrepresented pathways among differentially expressed proteins
[35]. Two major clusters of highly connected downregulated proteins
were identified based on GO term analyses (Supplementary Fig. 3A).
Pathway analyses per cluster revealed an enrichment for pathways
Fig. 4. Differentially expressed proteins relate to chronic kidney disease stage.
Mean normalized protein count of downregulated proteins (blue) and upregu-
lated proteins (red) is associated with stage of CKD in NPH-RC patients. Dots
represent individual proteins. Lines and error bars show mean and standard
deviation, respectively. The most highly abundant proteins are labeled with
protein names. *P < .05, ****P < .0001, calculated using Mann-Whitney test.
CKD: chronic kidney disease. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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related to ‘signaling’, ‘transport’ and ‘phagocytosis’ (with overlapping
genes involved), ‘endocytosis’ and ‘adherens junctions’ among down-
regulated proteins in both clusters (Supplementary Fig. 3B). In the
subgroup of patients with isolated NPH (n=6), pathways enriched
among downregulated proteins included specific cilia-associated path-
ways such as ‘cargo trafficking to the periciliary membrane’ (P= .002)
and the ‘polycystic kidney disease pathway’ (P= .004) (data not
shown). Significantly enriched pathways among three clusters of up-
regulated proteins comprised ‘signaling’, ‘extracellular matrix organi-
zation’, and ‘coagulation and complement cascades’ (Supplementary
Fig. 3C and D). These findings from pathway analyses, including
overrepresentation of ‘signaling’ and ‘endocytosis’ pathways among
downregulated proteins and ‘extracellular matrix organization’ path-
ways among upregulated proteins, were consistent with down- and
upregulated GO terms.
3.4. Candidate biomarkers for nephronophthisis
The top five most discriminating downregulated proteins (PELI2,
HRAS, VPS9D1, CPNE5, and SIRPA) and upregulated proteins (BPGM,
CANX, PRL, CDH5, and ART3) based on fold change included two
proteins (CANX and PRL) that have previously been reported to be
upregulated in plasma and urine of patients with kidney diseases
(Fig. 6, Table 3) [37, 38]. The other eight most discriminating proteins
have not previously been described in the context of CKD and are po-
tential novel biomarkers for ciliopathy-related CKD. NGAL, which has
previously been described as a biomarker for kidney injury and was
reported to be elevated in urine of ciliopathy patients [39], was mod-
erately upregulated in patients (fold change 2.4, P < .05).
To assess the occurrence of cilia-associated proteins among poten-
tial biomarkers for NPH-RH, we used the SysCilia Gold Standard
(Version 1) list of 303 confirmed ciliary genes (Supplementary Table 6)
[40]. Five out of 156 differentially expressed proteins corresponded to
known ciliary genes. Four proteins (PKD1, ARL13B, SMO, and RP2;
Supplementary Fig. 4A-D) were downregulated (average fold changes
9.9, 6.8, 4.5, and 4.1 respectively; P < .05) and one protein (FLNA)
was upregulated (fold change 4.0) in urinary EVs of NPH-RC patients
(Supplementary Fig. 4E). Ciliopathy genes that were mutated in the
NPH-RC patients (Supplementary Table 5) were not represented in the
downregulated ciliary proteins, suggesting that gene mutations globally
affect ciliary pathways and are not restricted to a narrow effect.
A PubMed literature search was performed to list proteins expressed
in whole urine that were previously associated with CKD
(Supplementary Methods and Supplementary Table 7). Comparison of
70 CKD-associated proteins acquired from the literature with the 156
discriminating markers in our NPH-RC cohort showed that 3/156 pro-
teins correspond to known CKD-associated urinary proteins. Of these,
two proteins (MMP7 and PLTP) were upregulated in NPH-RC patients
described in the current study, corresponding to the direction of fold
change described in literature [41, 42]. One downregulated protein in
NPH-RC patients (ACE2) showed a different direction of fold change in
urinary EVs compared to the direction of fold change described in lit-
erature [43]. This could be the result of the different compartment that
was analyzed, namely urinary EVs instead of whole urine.
4. Discussion
Here we report that protein expression profiles in urinary EVs can
distinguish NPH-RC patients (n= 12) from healthy controls (n= 12)
that were analyzed as individual samples. By using an in-depth pro-
teomics analysis using 140 nanoLC-MS/MS runs on a high resolution
fast scanning tandem mass spectrometer, combined with statistical and
quantitative filtering, we identified 156 promising candidate protein
biomarkers. Importantly, expression levels of the most discriminating
proteins were associated with CKD stage in patients, suggesting a re-
lation to disease-state and a potential prognostic value. Thus, urinaryTa
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EVs form a promising non-invasive source of biomarkers for early de-
tection and prognostics of nephronophthisis. Further research is needed
to determine the specificity of these candidate biomarkers for NPH-RC.
Underscoring the validity of our systematic and unbiased inter-
rogation of differentially expressed proteins in biofluid of NPH-RC pa-
tients, we found a significant upregulation of neutrophil gelatinase-as-
sociated lipocalin (NGAL) protein in NPH-RC patients. NGAL is the only
biomarker for kidney injury in general that was previously identified in
NPH-RC patients. An elevation of serum and whole urine NGAL protein
levels has been reported in three patients with nephronophthisis-related
Joubert syndrome [39]. This makes NGAL an interesting biomarker for
further investigation.
GO terms and pathways enriched among proteins downregulated in
NPH-RC patients were related to signaling, actin cytoskeleton re-
organization and endocytosis. This could reflect a role for these proteins
in cilia formation and in ciliary signaling pathways including the mTOR
signaling pathway that was enriched among downregulated proteins.
Alternatively, these GO terms and pathways could reflect a role in the
(EV-mediated) response to kidney damage in general, similar to en-
riched GO terms and pathways among upregulated proteins, which
were associated with extracellular matrix organization and response to
wounding. Consequently, it is unclear whether the overrepresented
pathways identified in this study point towards ciliopathy-specific dis-
ease mechanisms. Although cilia-associated pathways were over-
represented among downregulated proteins in patients with isolated
nephronophthisis, including ‘cargo trafficking to the periciliary mem-
brane’ and the ‘polycystic kidney disease pathway’, the limited number
of patients per NPH-RC subgroup precludes firm conclusions about
differences in pathogenesis of various NPH-RC syndromes.
The 114 discriminating downregulated proteins in urinary EVs of
patients included cilia-associated proteins ARL13B, PKD1, RP2 and
SMO. In addition, the top 20 downregulated proteins included the re-
cently validated ciliary protein serine/threonine-protein kinase 11
(STK11) [44, 45]. Previous studies in polycystic kidney disease (PKD)
patients have demonstrated significantly different expression levels of
cilia-specific membrane proteins in urine EVs of patients compared to
controls, supporting our finding that ciliary proteins are present in
urine EVs and that their abundance can reflect disease state [46, 47].
Although the 156 discriminating markers could contain novel ciliary
proteins, these proteins are also in part associated with CKD in general.
As a result, the single cilia-associated proteins discussed above could be
more specific biomarkers for nephronophthisis than the discriminating
set of 156 proteins.
Two of the top five most discriminating upregulated proteins, cal-
nexin (CANX) and prolactin (PRL), have previously been implicated in
kidney diseases. CANX is a calcium-binding protein involved in the
retention of incorrectly folded proteins within the endoplasmatic re-
ticulum. CANX showed higher expression levels in plasma of renal cell
carcinoma patients compared to controls [37]. A study in patients with
diabetic nephropathy demonstrated increased levels of PRL in urine of
Fig. 5. Results from gene ontology (GO) term enrichment analysis of differentially expressed proteins in urinary extracellular vesicles (EVs) from NPH-RC patients.
GO terms related to A) overrepresented biological processes, B) cellular components, and C) molecular functions were significantly associated with differentially
expressed proteins in NPH-RC patients compared to controls by fold enrichment (P < .05). Fraction represents the number of genes detected/number of reference
genes per GO term.
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patients compared to controls [38]. Our study corroborates that CANX
and PRL are CKD-associated markers and identifies additional dis-
criminating proteins including ART3 and CDH5 as candidate bio-
markers for (ciliopathy-related) CKD. These highly differentially ex-
pressed proteins should be investigated further in larger NPH-RC
patient cohorts.
The upregulated proteins that showed a strong correlation with CKD
stage included Versican core protein (VCAN) (Fig. 4). VCAN is an ex-
tracellular matrix proteoglycan with normally low expression in kid-
neys [48]. Higher mRNA expression of VCAN in renal biopsies was
reported to be correlated to histologic damage and progression of CKD
[49]. By contrast, Dipeptidase 1 (DPEP1) and Protocadherin Fat 4
(FAT4) were decreased in urinary EVs of patients. DPEP1 is a kidney-
specific protein that is involved in the metabolism of several proteins by
dipeptide hydrolysis. In line with our findings, DPEP1 was found to be
downregulated in the urine of focal segmental glomerulosclerosis
(FSGS) patients compared to controls [50]. FAT4 is a planar cell po-
larity protein that localizes to cilia in kidney cells [51]. Importantly,
loss of Fat4 causes cystic kidney disease in mice [51]. The connection to
cilia and cystic kidney disease makes FAT4 an interesting candidate
biomarker for nephronophthisis. In addition, although FAT4 is not
among the top five most discriminating markers based on fold change,
its association with disease severity indicates potential prognostic
value.
This study has several limitations. First, we did not investigate the
specificity of the differentially expressed proteins. Therefore, compar-
ison with a cohort of patients with early-onset CKD due to other causes
is required to discern whether our top identified proteins are specific for
NPH-RC or reflect CKD in general. Second, the identified markers need
to be validated in larger patient cohorts in order to be able to stratify for
disease subgroups. Third, longitudinal follow-up of individuals will
establish whether urinary EV protein signatures can accurately predict
Fig. 6. Box plots of top 5 most differentially expressed proteins in patients and
controls based on normalized spectral counts. Lines and whiskers show median,
minimum and maximum values. **P < .01, ***P < .001, ****P < .0001,
calculated using Mann-Whitney test.
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disease onset in individuals with biallelic NPH-mutations and serve as
prognostic markers.
5. Conclusions
To our knowledge this is the first report on an in-depth clinical
proteomics dataset of global urinary EVs proteomics in well-char-
acterized NPH-RC patients. Our data show that measuring protein
profiles in urinary EVs is a promising approach for non-invasive early
diagnostics and prognostics in patients with NPH-RC. Since the current
diagnostics and prognostics toolbox for nephronophthisis is far from
complete, early biomarkers indicative of disease will be of great benefit
to NPH-RC patients and their relatives.
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